Cargando…
Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a heterogeneous distribution across racial and ethnic groups, with a disproportionate burden among Hispanics. Although there are currently no approved therapies for treatment of NAFLD, several therapies have been investigated in clinical tria...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475777/ https://www.ncbi.nlm.nih.gov/pubmed/32952877 http://dx.doi.org/10.4254/wjh.v12.i8.506 |
_version_ | 1783579582271586304 |
---|---|
author | Patel, Parita Muller, Charles Paul, Sonali |
author_facet | Patel, Parita Muller, Charles Paul, Sonali |
author_sort | Patel, Parita |
collection | PubMed |
description | BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a heterogeneous distribution across racial and ethnic groups, with a disproportionate burden among Hispanics. Although there are currently no approved therapies for treatment of NAFLD, several therapies have been investigated in clinical trials. AIM: To analyze the inclusion of racial and ethnic minority groups in clinical trials for NAFLD. METHODS: We performed a systematic review of North American, English-language, prospective studies for NAFLD therapies published from 2005 to 2019. Racial and ethnic enrollment data were recorded for each eligible study. Meta-analysis was performed to compute pooled prevalence of different racial and ethnic groups, followed by further subgroup analyses. These analyses were based on diagnosis of non-alcoholic steatohepatitis (NASH) and timing of study on enrollment by ethnicity. Descriptive statistics were performed to compare racial and ethnic study enrollment to previously reported NAFLD population prevalence. RESULTS: Thirty-eight studies met criteria for inclusion in the systematic review. When reported, median age of enrolled subjects was 49 years (range 41.5-58) with 56% female participants. NAFLD was defined through biopsy findings in 79% (n = 30) of the studies. Of the included articles, treatment modalities ranged from medications (n = 28, 74%), lifestyle interventions (n = 5, 13%), bariatric surgery (n = 4, 11%) and phlebotomy (n = 1, 2%). Twenty-eight studies (73%) included racial and/or ethnic demographic information, while only 17 (45%) included information regarding Hispanic participation. Of the 2983 patients enrolled in all eligible trials, a total of only 346 (11.6%) Hispanic participants was reported. Meta-analysis revealed a pooled Hispanic prevalence of 24.3% (95% confidence interval 16.6-32.0, I(2) 94.6%) among studies documenting Hispanic enrollment. Hispanic enrollment increased over time from 15% from 2005-2014 to 37% from 2015-2019. CONCLUSION: In a meta-analysis of NAFLD trials, documentation of racial/ethnic demographic data occurred in less than half of studies. Standardization of reporting of race/ethnicity and targeted interventions toward minority recruitment are needed to improve diversity of enrollment. |
format | Online Article Text |
id | pubmed-7475777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-74757772020-09-18 Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis Patel, Parita Muller, Charles Paul, Sonali World J Hepatol Meta-Analysis BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a heterogeneous distribution across racial and ethnic groups, with a disproportionate burden among Hispanics. Although there are currently no approved therapies for treatment of NAFLD, several therapies have been investigated in clinical trials. AIM: To analyze the inclusion of racial and ethnic minority groups in clinical trials for NAFLD. METHODS: We performed a systematic review of North American, English-language, prospective studies for NAFLD therapies published from 2005 to 2019. Racial and ethnic enrollment data were recorded for each eligible study. Meta-analysis was performed to compute pooled prevalence of different racial and ethnic groups, followed by further subgroup analyses. These analyses were based on diagnosis of non-alcoholic steatohepatitis (NASH) and timing of study on enrollment by ethnicity. Descriptive statistics were performed to compare racial and ethnic study enrollment to previously reported NAFLD population prevalence. RESULTS: Thirty-eight studies met criteria for inclusion in the systematic review. When reported, median age of enrolled subjects was 49 years (range 41.5-58) with 56% female participants. NAFLD was defined through biopsy findings in 79% (n = 30) of the studies. Of the included articles, treatment modalities ranged from medications (n = 28, 74%), lifestyle interventions (n = 5, 13%), bariatric surgery (n = 4, 11%) and phlebotomy (n = 1, 2%). Twenty-eight studies (73%) included racial and/or ethnic demographic information, while only 17 (45%) included information regarding Hispanic participation. Of the 2983 patients enrolled in all eligible trials, a total of only 346 (11.6%) Hispanic participants was reported. Meta-analysis revealed a pooled Hispanic prevalence of 24.3% (95% confidence interval 16.6-32.0, I(2) 94.6%) among studies documenting Hispanic enrollment. Hispanic enrollment increased over time from 15% from 2005-2014 to 37% from 2015-2019. CONCLUSION: In a meta-analysis of NAFLD trials, documentation of racial/ethnic demographic data occurred in less than half of studies. Standardization of reporting of race/ethnicity and targeted interventions toward minority recruitment are needed to improve diversity of enrollment. Baishideng Publishing Group Inc 2020-08-27 2020-08-27 /pmc/articles/PMC7475777/ /pubmed/32952877 http://dx.doi.org/10.4254/wjh.v12.i8.506 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Meta-Analysis Patel, Parita Muller, Charles Paul, Sonali Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title | Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title_full | Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title_fullStr | Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title_full_unstemmed | Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title_short | Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis |
title_sort | racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: a systematic review and meta-analysis |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475777/ https://www.ncbi.nlm.nih.gov/pubmed/32952877 http://dx.doi.org/10.4254/wjh.v12.i8.506 |
work_keys_str_mv | AT patelparita racialdisparitiesinnonalcoholicfattyliverdiseaseclinicaltrialenrollmentasystematicreviewandmetaanalysis AT mullercharles racialdisparitiesinnonalcoholicfattyliverdiseaseclinicaltrialenrollmentasystematicreviewandmetaanalysis AT paulsonali racialdisparitiesinnonalcoholicfattyliverdiseaseclinicaltrialenrollmentasystematicreviewandmetaanalysis |